DB15849InvestigationalVaccines
The University of Queensland (UQ), in partnership with The Coalition for Epidemic Preparedeness Inovations (CEPI) and CSL has developed a COVID-19 candidate, SARS-CoV-2 Sclamp. The vaccine was developed using UQ’s... The vaccine was developed using UQ’s rapid response ‘molecular clamp’ vaccine platform that locks surface proteins in a configuration that allows more robust immune responses, in combination with a well-established adjuvant technology, MF59, from Seqirus.
- Also known as
- SARS-CoV-2 Sclamp adjuvanted vaccine · UQ COVID-19 Vaccine · UQ-1-SARS-CoV-2-Sclamp
- Code names
- SARS-CoV-2 Sclamp
What you can answer from here — as of September 18, 2020
Which companies are running trials of SARS-CoV-2 Sclamp, in which indications and phases, and which of those programs are still active?
Create a free account or log in to explore the full data card.
Create Account